About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.
About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.